Abstract

During the past year, the VRC's Vector Core created and tested new vaccine vectors expressing novel forms of envelope proteins. In addition, work continued to test different methods and routes of administration as well as prime/boost combinations to further optimize HIV vaccine strategies. DNA, VLP, nanoparticles and other vectors were tested. Several candidate vaccines that elicited promising immunogenicity data in preliminary studies are being tested further. Studies to develop and test bi-specific antibodies expressing 2 types of antibody with the goals of improving immunogenicity against HIV and targeting latent virus. In addition, studies continued to analyze ferritin nanoparticles expressing HIV envelope to induce CD4bs antibodies, identified by newly developed assays based on the resurfaced stabilized gp120 core with antigenic specificity for the initial site of CD4 attachment of gp120. Epitopes recognized by vectors expressing neutralizing antibodies were also analyzed and tested for their ability to induce similar types of antibodies, in vivo.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAAI005002-14
Application #
9161741
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
2015
Total Cost
Indirect Cost

  Institution

Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Zhou, Tongqing; Doria-Rose, Nicole A; Cheng, Cheng et al. (2017) Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. Cell Rep 19:719-732
Chuang, Gwo-Yu; Geng, Hui; Pancera, Marie et al. (2017) Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. J Virol 91:
Cheng, Cheng; Pancera, Marie; Bossert, Adam et al. (2016) Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody. J Virol 90:2740-55
Saunders, Kevin O; Pegu, Amarendra; Georgiev, Ivelin S et al. (2015) Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. J Virol 89:5895-903
Georgiev, Ivelin S; Joyce, M Gordon; Yang, Yongping et al. (2015) Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. J Virol 89:5318-29
Lynch, Rebecca M; Wong, Patrick; Tran, Lillian et al. (2015) HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J Virol 89:4201-13
Cheng, Cheng; Wang, Lingshu; Ko, Sung-Youl et al. (2015) Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development. Vaccine 33:7344-51
Ko, Sung-Youl; Pegu, Amarendra; Rudicell, Rebecca S et al. (2014) Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514:642-5
Pancera, Marie; Zhou, Tongqing; Druz, Aliaksandr et al. (2014) Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514:455-61
Pegu, Amarendra; Yang, Zhi-yong; Boyington, Jeffrey C et al. (2014) Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med 6:243ra88

Showing the most recent 10 out of 18 publications